Treatment of platinum-resistant ovarian cancer. Expert Opin Pharmacother. 2001; 2 :1299–1306. doi: 10.1517/14656566.2.8.1299. [ Cross Ref ]Trimble EL, Wright J, Christian MC. Treatment of platinum-resistant ovarian cancer. Expert Opin Pharmacother 2001; 2: 1299-306....
Platinum is a key component of ovarian cancer systemic therapy. However, most patients will eventually face a recurrence, leading to chemotherapy resistance, especially against platinum. For individuals with platinum-resistant ovarian cancer (PROC), treatment options are limited, and their survival prospe...
By using platinum sensitive A2780 and resistant C200 ovarian cancer cell lines, we are able to show that metabolite al- terations can clearly separate the cells based on their platinum sensitivity. We identified significant metabolite variations in 6 different metabolic pathways participating in ...
The objective was to determine the response rate to platinum retreatment of "platinum-resistant" ovarian cancer after intervening nonplatinum therapy. We retrospectively identified 30 patients with platinum-resistant ovarian cancer who received nonplatinum chemotherapy for recurrent epithelial ovarian cancer pr...
cancer progression. Expression of differentially expressed proteins was assessed in ovarian tumors obtained from platinum-sensitive (n = 15) versus platinum-resistant patients (n = 10), as well as matching tumors from patients at initial diagnosis and following relapse (n = 4). ...
Ovarian cancer is a prevalent gynecologic malignancy with the second-highest mortality rate among gynecologic malignancies. Platinum-based chemotherapy is the first-line treatment for ovarian cancer; however, a majority of patients with ovarian cancer ex
Platinum is a key component of ovarian cancer systemic therapy. However, most patients will eventually face a recurrence, leading to chemotherapy resistance, especially against platinum. For individuals with platinum-resistant ovarian cancer (PROC), trea
discriminate between platinum-resistant and platinum-sensitive tumors before they recur," explains Kajiyama. "Using this method, early diagnosis of platinum resistance and selection of appropriate postoperative anticancer therapy for patients as well as a new ovarian cancer treatment strategy are ...
2856 ChinMedJ2oo9:122{23):2856—2860 Originalarticle Treatmentofplatinum—resistantrecurrentovariancancerusinga ‘‘predictivemoleculetargetedroutinechemotherapy’’system ZHAOXiao—dong,WEIFeng—hua,ZHANGYi,HEShu—rongandYANGLi Keywords:ovarianneoplasms;recurrence;chemotherapy;predictivemolecule Background Correctdru...
To further confirm that C/EBPβ promotes cisplatin resistance in ovarian cancer, C/EBPβ was overexpressed in OV2008, which is a cisplatin-sensitive cell line with negligible C/EBPβ expression, and C/EBPβ was knocked down in C13* cells, which are cisplatin-resistant derivatives of OV2008 ...